NEW YORK (GenomeWeb News) – Celera has extended an existing licensing agreement for Nanogen's Minor Groove Binder technology that will enable it to develop additional diagnostic products, Nanogen said today.
Celera originally licensed the MGB technology in 2004 from Epoch Biosciences to develop hepatitis C genotyping products for patient management, monitoring, and treatment. Nanogen acquired Epoch for $97 million later that year.
Under the expanded agreement, Celera will use the MGB technology to develop in vitro diagnostic products for cardiovascular and oncological applications, Nanogen said.
Nanogen said that Celera will provide an upfront license fee, milestone and anniversary fees throughout development, and a royalty on sales of the diagnostic products.